China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug HS-10518 (TU2670). The study will focus on the treatment of moderate to severe pain associated with endometriosis and menorrhagia associated with uterine fibroid.
Expanding Access to Treatment with TiumBio Partnership
In August 2022, Hansoh entered into a licensing agreement with South Korea-based TiumBio Co., Ltd, securing exclusive development and commercialization rights to HS-10518 in Greater China. HS-10518 is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist, which offers a potential new treatment option for patients suffering from gynecological conditions such as endometriosis and uterine fibroids.
Clinical Study Significance and Potential Impact
The clinical study’s approval by the NMPA is a significant step forward in the development of HS-10518. It indicates the potential for Hansoh Pharmaceutical to provide a new therapeutic option for managing pain in endometriosis and menorrhagia, conditions that affect a significant number of women. The partnership with TiumBio further strengthens Hansoh’s position in the region, as it looks to expand access to innovative treatments for these underserved medical needs.-Fineline Info & Tech
